SCHEMBL24490489

SCHEMBL24490489

CCC1(CC)c2ccccc2-c2ccc(C(=O)/C(CC3CCCCC3)=N/OC(=O)c3ccccc3)cc21

nearest known ligand 0.41

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.37
▸ PDK2 Q15119 8/20 0.37
▸ ALDH1A1 P00352 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25711214 0.93 POLB (0.34) POLBPDK2ALDH1A1
SCHEMBL24497049 0.93 POLB (0.36) POLBPDK2ALDH1A1L3MBTL1
SCHEMBL24490466 0.92 PDK2 (0.36) POLBPDK2
SCHEMBL24497048 0.91 POLB (0.35) POLBPDK2ALDH1A1
SCHEMBL24490483 0.91 PDK2 (0.38) POLBPDK2ALDH1A1
SCHEMBL24490440 0.90 PDK2 (0.39) POLBPDK2
SCHEMBL24497051 0.89 PDK2 (0.38) POLBPDK2ALDH1A1L3MBTL1LMNA
SCHEMBL24490488 0.84 PPM1D (0.34) POLBPDK2
SCHEMBL18123001 0.84 PDK2 (0.37) POLBPDK2ALDH1A1
SCHEMBL18122990 0.83 PDK2 (0.37) POLBPDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239922-A1 PHOTOCURABLE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239922-A1 PHOTOCURABLE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20230242692-A1 COMPOSITION AND CURED PRODUCT TOKYO OHKA KOGYO CO., LTD. (JP) 2023-08-03 — — US disclosed
US-20230242692-A1 COMPOSITION AND CURED PRODUCT TOKYO OHKA KOGYO CO., LTD. (JP) 2023-08-03 — — US disclosed
WO-2023047856-A1 COMPOSITION AND PHOTOSENSITIVE COMPOSITION 東京応化工業株式会社 2023-03-30 — — WO disclosed
US-20230002520-A1 CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT TOKYO OHKA KOGYO CO., LTD. (JP) 2023-01-05 — — US disclosed
US-20220177673-A1 CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2022-06-09 — — US disclosed
US-20220177625-A1 CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2022-06-09 — — US disclosed
US-20220177641-A1 CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2022-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177625-A1 CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND CROCC, RCSD1, CRYZ POLB 1371/4885PDK2 4077/4885ALDH1A1 2462/4885
US-20220177641-A1 CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND CROCC, RCSD1, WDR5 POLB 1946/4885PDK2 4363/4885ALDH1A1 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback